

BP-50623

Tarlatamab Biosimilar – Anti-GPRC5D/CD3 Bispecific Antibody

Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.

Product Details	
Species Reactivity	Human
Source	Mammalian Cells
Isotype	Human IgG1 kappa
Class	Anti-Human Bispecific antibodies
Type	Recombinant Humanized
Clone	NA
Target	Anti-human DLL3/CD3
Purity	>99%
Molecular Weight	105.07 kDa
CAS Number	2307488-83-9
Formulation	NA
Storage conditions	Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws Addition of 20 to 40 % glycerol may improve cryoprotection. Purified antibodies should ideally be stored as 0.5 to 2.0 mg/ml stock solutions. Aliquot the product according to your needs to avoid freeze/thaw cycles.